Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study - PubMed (original) (raw)
Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study
Rosalynn M Nazarian et al. J Cutan Pathol. 2010 Apr.
Abstract
Background: The elucidation of protein biomarkers that are differentially expressed in human melanocytic tumors during tumor progression may lead to the identification of therapeutic targets and novel diagnostic tests. In a meeting chaired by Dr Mihm, a list of biomarkers of interest in melanoma was compiled. The specialized programs of research excellence (SPORE) in skin cancer developed a melanocytic tumor progression tissue microarray (TMA) to evaluate these candidate biomarkers. In addition to markers reported elsewhere, we evaluated c-Kit, MITF, MART1, HMB-45 and bcl-2.
Methods: The TMA contains 480 cores of benign nevi, primary cutaneous melanoma and melanoma metastases. Immunohistochemical detection of melanoma biomarkers, including c-Kit, MITF, MART-1, HMB-45 and bcl-2 was performed.
Results: Intense nuclear staining for MITF protein was observed in 83% of nevi, 56% of primary melanomas and 23% of metastases. Bcl-2 expression was reduced with progression to metastasis (detected in 86, 89 and 52% of nevi, primaries and metastases, respectively), contrary to MART-1, which showed no differential expression (74, 85 and 84%). HMB-45 was observed in 18% of nevi and most (72 and 75%) primary melanomas and metastases. c-Kit protein increased with progression from nevi to primary tumor (10 and 77% of cases, respectively) and was decreased in metastases (26% of cases).
Conclusions: Through a collaboration of the Skin SPOREs sponsored by the Organ Systems Branch of the National Cancer Institute (NCI), we identified a list of melanoma biomarkers of interest, developed a melanocytic tumor progression TMA and completed a coordinated analysis of these biomarkers. This TMA has served as a powerful validation tool for newly identified and known melanoma biomarkers by revealing trends in expression during tumor progression and by confirming the heterogeneity of biomarker expression in cutaneous melanocytic tumors.
Similar articles
- Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT, van Belle P, Elenitsas R, Elder DE. Montone KT, et al. Mod Pathol. 1997 Sep;10(9):939-44. Mod Pathol. 1997. PMID: 9310959 - bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA, From L, Kahn HJ. Ramsay JA, et al. Mod Pathol. 1995 Feb;8(2):150-4. Mod Pathol. 1995. PMID: 7777475 - Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS, Shakhtour B, Shyr Y. Boyd AS, et al. J Am Acad Dermatol. 2008 May;58(5):750-4. doi: 10.1016/j.jaad.2007.12.026. Epub 2008 Feb 4. J Am Acad Dermatol. 2008. PMID: 18249467 - Prognostic tissue markers in melanoma.
Moore DA, Pringle JH, Saldanha GS. Moore DA, et al. Histopathology. 2012 Apr;60(5):679-89. doi: 10.1111/j.1365-2559.2011.03910.x. Epub 2011 Aug 22. Histopathology. 2012. PMID: 21880059 Review. - Diagnostic utility of epithelial and melanocitic markers with double sequential immunohistochemical staining in differentiating melanoma in situ from invasive melanoma.
Parra-Medina R, Morales SD. Parra-Medina R, et al. Ann Diagn Pathol. 2017 Feb;26:70-74. doi: 10.1016/j.anndiagpath.2016.07.010. Epub 2016 Aug 17. Ann Diagn Pathol. 2017. PMID: 27594302 Review.
Cited by
- Slug expression during melanoma progression.
Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, Kusewitt DF. Shirley SH, et al. Am J Pathol. 2012 Jun;180(6):2479-89. doi: 10.1016/j.ajpath.2012.02.014. Epub 2012 Apr 13. Am J Pathol. 2012. PMID: 22503751 Free PMC article. - Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg S, Chan JL, Namkoong J, Goydos JS, Chen S. Lee HJ, et al. Clin Cancer Res. 2011 Nov 15;17(22):7080-92. doi: 10.1158/1078-0432.CCR-11-0098. Epub 2011 Aug 15. Clin Cancer Res. 2011. PMID: 21844014 Free PMC article. - In melanoma, beta-catenin is a suppressor of invasion.
Arozarena I, Bischof H, Gilby D, Belloni B, Dummer R, Wellbrock C. Arozarena I, et al. Oncogene. 2011 Nov 10;30(45):4531-43. doi: 10.1038/onc.2011.162. Epub 2011 May 16. Oncogene. 2011. PMID: 21577209 Free PMC article. - Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.
Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Tanese K, et al. J Invest Dermatol. 2015 Nov;135(11):2775-2784. doi: 10.1038/jid.2015.204. Epub 2015 Jun 3. J Invest Dermatol. 2015. PMID: 26039541 Free PMC article. - The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE, Wan X, Roth JS, Liewehr DJ, Sealover NE, Frye WJE, Kim A, Stauffer S, Perkins OL, Sun W, Isanogle KA, Robinson CM, James A, Awasthi P, Shankarappa P, Luo X, Lei H, Butcher D, Smith R, Edmondson EF, Chen JQ, Kedei N, Peer CJ, Shern JF, Figg WD, Chen L, Hall MD, Difilippantonio S, Barr FG, Kortum RL, Robey RW, Vaseva AV, Khan J, Yohe ME. Hebron KE, et al. Clin Cancer Res. 2023 Jan 17;29(2):472-487. doi: 10.1158/1078-0432.CCR-22-1646. Clin Cancer Res. 2023. PMID: 36322002 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical